HEAD-TO-HEAD

ORAL GLP-1 RECEPTOR MIMETIC VS GLP-1 / GIP DUAL AGONIST

the oral GLP-1 mimetic and the GLP-1/GIP dual agonist come from the same the originator pharma sponsor pipeline but represent two different pharmacology bets. the oral GLP-1 mimetic is a small-molecule oral GLP-1 receptor allosteric agonist (once-daily tablet). the GLP-1/GIP dual agonist is a peptide dual GLP-1 + GIP receptor agonist (once-weekly subcutaneous injection). Oral convenience vs injectable dual-receptor coverage.

A · No. 020

ORAL GLP-1 RECEPTOR MIMETIC

Small-molecule receptor activator

B · No. 002

GLP-1 / GIP DUAL AGONIST

Combined incretin receptor activation

SIDE BY SIDE

FIELD

A · ORAL GLP-1 RECEPTOR MIMETIC

B · GLP-1 / GIP DUAL AGONIST

Class

Non-peptide small-molecule oral GLP-1R agonist

Synthetic peptide · dual GLP-1R + GIPR agonist

Development code

LY3502970

LY3298176

Route

Oral (once-daily tablet)

Subcutaneous (once-weekly injection)

Half-life

~24-30 hours

~5 days

Receptors engaged

GLP-1R only (allosteric site)

GLP-1R + GIPR

Best published Phase 2 outcome

-14.7% placebo-subtracted BW at 45 mg/d, 36 wk (Wharton 2023 NEJM)

-22.5% BW at 72 wk, 15 mg (SURMOUNT-1)

FDA status

Investigational · Phase 3 ACHIEVE / ATTAIN ongoing

FDA-approved (the FDA-approved class member 2022, the FDA-approved class member 2023)

Oral-medication absorption notes

No dietary restriction reported in Phase 2

Not oral; delayed gastric emptying may alter co-administered oral drug absorption

WHICH IS BETTER · BY GOAL

▶ Oral convenience for research / patient complianceA · ORAL GLP-1 RECEPTOR MIMETIC

the oral GLP-1 mimetic is the first oral GLP-1 candidate that does not require the specialized absorption formulation of oral the long-acting GLP-1 agonist (no empty-stomach, no 30-min wait, no limited water). Major compliance edge if it reaches approval.

▶ Maximum body-weight reduction (head-to-head Phase 2 numbers)B · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist 15 mg reached -22.5% BW at 72 weeks in SURMOUNT-1. the oral GLP-1 mimetic 45 mg reached -14.7% placebo-subtracted at 36 weeks. Different trial durations but the absolute number favors the GLP-1/GIP dual agonist.

▶ Validated human-prescription pathwayB · GLP-1 / GIP DUAL AGONIST

the GLP-1/GIP dual agonist is FDA-approved with years of post-marketing data. the oral GLP-1 mimetic remains investigational.

▶ Single-receptor mechanism simplicityA · ORAL GLP-1 RECEPTOR MIMETIC

the oral GLP-1 mimetic acts only at GLP-1R via an allosteric site. For research isolating GLP-1R contribution from other incretin receptors, the oral GLP-1 mimetic is the cleaner pharmacological probe.

STACKING NOTE

Combining multiple GLP-1R agonists is not supported by published research; the pathway is the same and combined use is unstudied. Buyers researching the GLP-1 category often order both as parallel oral vs injectable reference compounds.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶